Cargando…

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status

The clinical benefit of adding platinum to adjuvant chemotherapy for patients with triple-negative breast cancer (TNBC) has not been well investigated, although it was associated an improved response rate in neoadjuvant setting. We retrospectively analyzed the time to tumor progression (TTP) and ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Ying-Wen, Hung, Chia-Yen, Lam, Hung-Bun, Chang, Yuan-Ching, Yang, Po-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Triple-Negative Breast Cancer - Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104219/ https://www.ncbi.nlm.nih.gov/pubmed/30150877 http://dx.doi.org/10.1177/1179554918794672

Ejemplares similares

Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort
por: Gonçalves, Homero, et al.
Publicado: (2018)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
por: Depypere, Herman, et al.
Publicado: (2021)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Mortality of Pregnancy Following Breast Cancer Diagnoses in Taiwanese Women
por: Chuang, Shu‐Chun, et al.
Publicado: (2019)

Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices
por: Ma, Wei-Li, et al.
Publicado: (2022)

Oocyte CTR1 is not essential for cisplatin-induced oocyte death of primordial follicle
por: Yu, Seok-Yeong, et al.
Publicado: (2022)

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy
por: Famoso, Justin M., et al.
Publicado: (2017)

Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies
por: Abuhadra, Nour, et al.
Publicado: (2022)

Narrowing Racial Gaps in Breast Cancer: Factors Affecting Probability of Adjuvant Radiation Therapy
por: Snead, Felicia, et al.
Publicado: (2019)

Impact of Adjuvant Radiation Therapy in Patients With Male Breast Cancer: A Multicenter International Analysis
por: Rolf, Daniel, et al.
Publicado: (2020)

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023)

Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer
por: Tan, Weige, et al.
Publicado: (2019)

Cardiovascular Risk After Adjuvant Trastuzumab in Early Breast Cancer: An Italian Population‐Based Cohort Study
por: Franchi, Matteo, et al.
Publicado: (2020)

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI
por: Veltman, J., et al.
Publicado: (2008)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

A Single-Institution Experience in the Preoperative Selection of DCIS Patients for IORT using the ASTRO Consensus Guidelines
por: Chin, Christine, et al.
Publicado: (2018)

Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan
por: Bardia, Aditya, et al.
Publicado: (2022)

Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment
por: Kim, Jinyong, et al.
Publicado: (2022)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis
por: Niikura, Naoki, et al.
Publicado: (2011)

Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: Role of fractionation and treatment volume
por: Parekh, Arti, et al.
Publicado: (2017)

A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial
por: Blackwell, Kimberly, et al.
Publicado: (2016)

Quantitative background parenchymal enhancement and fibro-glandular density at breast MRI: Association with BRCA status
por: Goodburn, Rosie, et al.
Publicado: (2023)

Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer
por: Lander, Eric M, et al.
Publicado: (2022)

Koebner phenomenon: Consideration when choosing fractionation for breast irradiation
por: Wu, Cheng-Chia, et al.
Publicado: (2017)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
Publicado: (2020)

Improved characterization of sub-centimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers
por: Lo Gullo, Roberto, et al.
Publicado: (2020)

Closed Incision Negative Pressure Therapy in Oncoplastic Surgery Prevents Delays to Adjuvant Therapy
por: Ockerman, Kyle M., et al.
Publicado: (2023)

Comparison of Breast Reconstruction Outcomes Using Oxychlorosene versus Triple Antibiotic Solution for Pocket Irrigation
por: Bamba, Ravinder, et al.
Publicado: (2022)

Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment
por: Litton, Jennifer K., et al.
Publicado: (2010)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience
por: McKee, Megan J., et al.
Publicado: (2016)

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Tamoxifen Initiation After Ductal Carcinoma In Situ
por: Nichols, Hazel B., et al.
Publicado: (2016)

Cardiac-sparing radiation therapy using positioning breast shell for patients with left-sided breast cancer who are ineligible for breath-hold techniques
por: Joseph, Kurian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6ig473ts6jh38ojjpg6basaiqb